

Certificate of Analysis

Product Name: PF 04449613

Catalog No.: 5915


Batch No.: 2

CAS Number: 1236858-52-8

IUPAC Name: 1,5-Dihydro-6-[(1*R*)-1-(3-phenoxy-1-azetidiny)ethyl]-1-(tetrahydro-2*H*-pyran-4-yl)-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula:	C ₂₁ H ₂₅ N ₅ O ₃
Batch Molecular Weight:	395.45
Physical Appearance:	White solid
Solubility:	DMSO to 100 mM 1eq. HCl to 10 mM with gentle warming
Storage:	Store at -20°C
Batch Molecular Structure:	



2. ANALYTICAL DATA

TLC:	R _f = 0.43 (Chloroform:Methanol [97:3])
HPLC:	Shows >99.1% purity
Chiral HPLC:	Shows >99.6% purity
¹H NMR:	Consistent with structure
Mass Spectrum:	Consistent with structure
Microanalysis:	
	Carbon Hydrogen Nitrogen
	Theoretical 63.78 6.37 17.7
	Found 63.61 6.45 17.31

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: PF 04449613

Catalog No.: 5915

Batch No.: 2

CAS Number: 1236858-52-8

IUPAC Name: 1,5-Dihydro-6-[(1*R*)-1-(3-phenoxy-1-azetidiny)ethyl]-1-(tetrahydro-2*H*-pyran-4-yl)-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one

Description:

Potent PDE9 inhibitor (IC₅₀ = 22 nM). Also exhibits a high affinity for cGMP (K_m ~170 nM). Brain penetrant.

Physical and Chemical Properties:


Batch Molecular Formula: C₂₁H₂₅N₅O₃

Batch Molecular Weight: 395.45

Physical Appearance: White solid

Minimum Purity: >98%

Batch Molecular Structure:



Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 100 mM

1eq. HCl to 10 mM with gentle warming

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold for research purposes under agreement from Pfizer Inc.

References:

Lee et al (2015) Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. *Nature* **519** 472. PMID: 25799991.

Claffey et al (2012) Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, *in vivo* active phosphodiesterase 9A inhibitors. *J.Med.Chem.* **55** 9055. PMID: 23025719.

Kleiman et al (2012) Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation *in vivo*. *J.Pharmacol.Exp.Ther.* **341** 396. PMID: 22328573.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel: +1 612 379 2956